Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

ABSTRACT: NIPISAFE is open-label, phase II study to identify a combination scheme of nivolumab and ipilimumab with a high level of clinical activity, but with a lower toxicity in MSI/dMMR metastatic colorectal cancer patients.

DISEASE(S): Colorectal Neoplasms,Colorectal Cancer Metastatic,Msi-h Colorectal Cancer

PROVIDER: 2365524 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR